header logo image

GENFIT Reports First Half-Year 2022 Financial Results and Provides Corporate Update

September 29th, 2022 1:49 am

Lille (France), Cambridge, MA; September 28, 2022 – GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with severe and chronic liver diseases, today announced its first half-year 2022 financial results and provided a corporate update.

View original post here:
GENFIT Reports First Half-Year 2022 Financial Results and Provides Corporate Update

Related Post

Comments are closed.


2024 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick